Literature DB >> 10487696

Identification of two novel deletion mutations within the Gs alpha gene (GNAS1) in Albright hereditary osteodystrophy.

D Yu1, S Yu, V Schuster, K Kruse, C L Clericuzio, L S Weinstein.   

Abstract

Albright hereditary osteodystrophy (AHO) is a genetic disorder characterized by short stature, skeletal defects, and obesity. Within AHO kindreds, some affected family members have only the somatic features of AHO [pseudopseudohypoparathyroidism (PPHP)], whereas others have these features in association with resistance to multiple hormones that stimulate adenylyl cyclase within their target tissues [pseudohypoparathyroidism type Ia (PHP Ia)]. Affected members of most AHO kindreds (both those with PPHP and those with PHP Ia) have a partial deficiency of Gs alpha, the alpha-subunit of the G protein that couples receptors to adenylyl cyclase stimulation, and in a number of cases heterozygous loss of function mutations within the Gs alpha gene (GNAS1) have been identified. Using PCR with the attachment of a high melting domain (GC-clamp) and temperature gradient gel electrophoresis, two novel heterozygous frameshift mutations within GNAS1 were found in two AHO kindreds. In one kindred all affected members (both PHP Ia and PPHP) had a heterozygous 2-bp deletion in exon 8, whereas in the second kindred a heterozygous 2-bp deletion in exon 4 was identified in all affected members examined. In both cases the frameshift encoded a premature termination codon several codons downstream of the deletion. In the latter kindred affected members were previously shown to have decreased levels of GNAS1 messenger ribonucleic acid expression. These results further underscore the genetic heterogeneity of AHO and provides further evidence that PHP Ia and PPHP are two clinical presentations of a common genetic defect. Serial measurements of thyroid function in members of kindred 1 indicate that TSH resistance progresses with age and becomes more evident after the first year of life.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487696     DOI: 10.1210/jcem.84.9.5970

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Postnatal establishment of allelic Gαs silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous Gαs disruption.

Authors:  Serap Turan; Eduardo Fernandez-Rebollo; Cumhur Aydin; Teuta Zoto; Monica Reyes; George Bounoutas; Min Chen; Lee S Weinstein; Reinhold G Erben; Vladimir Marshansky; Murat Bastepe
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

Review 2.  Genetics of congenital hypothyroidism.

Authors:  S M Park; V K K Chatterjee
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

Review 3.  The GNAS complex locus and human diseases associated with loss-of-function mutations or epimutations within this imprinted gene.

Authors:  Serap Turan; Murat Bastepe
Journal:  Horm Res Paediatr       Date:  2013-10-03       Impact factor: 2.852

4.  Cutaneous nodules and a novel GNAS mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature.

Authors:  Yun-Ling Li; Ting Han; Fang Hong
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

5.  Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification.

Authors:  N S Adegbite; M Xu; F S Kaplan; E M Shore; R J Pignolo
Journal:  Am J Med Genet A       Date:  2008-07-15       Impact factor: 2.802

Review 6.  Progressive osseous heteroplasia: diagnosis, treatment, and prognosis.

Authors:  Robert J Pignolo; Girish Ramaswamy; John T Fong; Eileen M Shore; Frederick S Kaplan
Journal:  Appl Clin Genet       Date:  2015-01-30

7.  A mouse model for osseous heteroplasia.

Authors:  Michael T Cheeseman; Kate Vowell; Tertius A Hough; Lynn Jones; Paras Pathak; Hayley E Tyrer; Michelle Kelly; Roger Cox; Madhuri V Warren; Jo Peters
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.